Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) Enterprise Value (2016 - 2025)

Dare Bioscience's Enterprise Value history spans 11 years, with the latest figure at -$24.7 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 57.42% year-over-year to -$24.7 million; the TTM value through Dec 2025 reached -$24.7 million, down 57.42%, while the annual FY2025 figure was -$24.7 million, 57.42% down from the prior year.
  • Enterprise Value reached -$24.7 million in Q4 2025 per DARE's latest filing, down from -$23.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$3.6 million in Q1 2024 to a low of -$51.7 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$21.4 million, with a median of -$16.1 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: tumbled 1006.64% in 2021, then soared 81.61% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$51.7 million in 2021, then surged by 32.91% to -$34.7 million in 2022, then soared by 69.78% to -$10.5 million in 2023, then tumbled by 49.85% to -$15.7 million in 2024, then plummeted by 57.42% to -$24.7 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Enterprise Value are -$24.7 million (Q4 2025), -$23.1 million (Q3 2025), and -$5.0 million (Q2 2025).